NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









PharmaBiome

PharmaBiome

Private
SchlierenHealthcare & Life Scienceshttps://www.pharmabiome.com/

Last Round

Seed

Jul 8, 2020

Total Funding Raised

$2.45M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

PharmaBiome is a biotechnology company that develops a drug development platform for targeted microbiome therapeutics to treat diseases caused by functional deficiencies in the microbiome.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

live biotherapeutic productsLBPsmicrobiome therapeuticsgut microbiomebacterial consortiapre-clinical biotechco-cultivation technologyrationally designed therapeuticspharmaceutical licensingbug-as-druginflammatory bowel diseaseIBDmicrobiome engineeringdrug discovery platformbiomanufacturinggastroenterology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

PharmaBiome Comparables

Compare PharmaBiome with similar companies based on industry and business-model similarity.

PharmaBiome comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
MarvelBiome Inc.
87%
ImmunoBiome Inc.
84%
mbiomics GmbH
81%

PharmaBiome Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedJul 8, 2020
GrantApr 23, 2020
AcceleratorJan 16, 2020
GrantMay 22, 2019
GrantDec 1, 2017
Grant
Jun 14, 2016

Key People

Founding team and executive leadership

Tomas de Wouters

Co-founder, CEO

Founding Team

PharmaBiome Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 16, 2026

    Monthly visitors increased 1915% MoM, from 46 to 927.

  • May 3, 2025

    Monthly visitors grew 31% MoM, reaching 1K.

PharmaBiome Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

PharmaBiome Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about PharmaBiome's valuation, stock price, and market status.

Firmographic Details

HeadquartersSchlieren
Employee Range11
Year Founded2015
Last FundingJul 8, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.